First AD

Second AD

Edgardo Santos, MD, FACP, FCCP, provides expert insights into the latest data from the TROPION-Lung01 trial.

Expert Perspectives on the Latest TROPION-Lung01 Data

® featuring Edgardo S. Santos, MD, FACP, FCCP.

Santos highlighted data from the phase 3 TROPION-Lung01 trial of datopotamab deruxtecan for patients with previously treated non–small cell lung cancer (NSCLC). Compared with docetaxel, datopotamab deruxtecan improved median progression-free survival to 4.4 from 3.7 months (HR, 0.75; 

=.004). Subgroup analyses showed benefit across most patient subsets, though docetaxel remained superior for squamous histology. Despite the progression-free survival gain, an increased risk of interstitial lung disease occurred with datopotamab deruxtecan (7 grade 5 cases). Nonetheless, results of this early trial suggest datopotamab deruxtecan has activity in NSCLC post–platinum-based chemotherapy.

Video synopsis is AI-generated and reviewed by

Lung Cancer

JAN-22-OSD1275 - /clinical/lung-cancer

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Insights

Insights is an expert interview video series of leading oncologists that provides in-depth reports and feature segments profiling leaders in a range of oncology disciplines, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecologic cancers, and hematologic malignancies. Most episodes feature 2 clinicians discussing the latest oncology advances in clinical practice. 

Recent Advancements in Treatment Approaches for NSCLC

Edgardo Santos, MD, FACP, FCCP, provides expert insights into the latest data from the TROPION-Lung01 trial, emphasizing the potential implications of this information for treating patients with non-actionable biomarkers in NSCLC.